Global Tuberculosis Diagnostics Market Size (2024 - 2029)

The tuberculosis diagnostics market is projected to experience growth over the forecast period, driven by an increasing burden of tuberculosis and multidrug-resistant tuberculosis. The market's expansion is supported by heightened research and development efforts, along with government initiatives and rising awareness in emerging markets. Despite the challenges posed by the COVID-19 pandemic, which negatively impacted diagnostic services, the demand for improved diagnostic tests and treatments is expected to propel market growth. However, high diagnostic costs and limited insurance coverage in emerging markets may impede this growth.

Market Size of Global Tuberculosis Diagnostics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
tuberculosis diagnostics market
Study Period 2019 - 2029
Market Size (2024) USD 2.44 Billion
Market Size (2029) USD 3.24 Billion
CAGR (2024 - 2029) 5.87 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Global Tuberculosis Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Tuberculosis Diagnostics Market Analysis

The Global Tuberculosis Diagnostics Market size is estimated at USD 2.44 billion in 2024, and is expected to reach USD 3.24 billion by 2029, growing at a CAGR of 5.87% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the data', it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has negatively impacted the market growth during the pandemic.

Certain factors that are propelling the market growth are the increasing burden of tuberculosis and multidrug-resistant tuberculosis (MDR-TB), increasing research and development investments and intensive product pipelines and increasing government initiatives, and rising awareness in the emerging markets.

The rising incidences of tuberculosis and multi-drug resistant tuberculosis (MDR-TB) is the key factor driving the market growth. For instance, according to the Global Tuberculosis Report 2021 published by the World Health Organization, in October 2021, most of the tuberculosis cases were found in the World Health Organization (WHO) regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%), and lesser numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), and Europe (2.3%). Additionally, according to the data published by the World Health Organization (WHO), in October 2021, about 1.5 million people worldwide died because of tuberculosis (TB), in 2020, and approximately 10 million people fell ill with tuberculosis globally. Thus, the rising burden of tuberculosis among the population increases the need for better diagnostic tests and treatment, which in turn is anticipated to propel the market growth over the forecast period.

Additionally, according to an article published by the Journal of Family Medicine and Primary Care, in January 2022, titled 'Status of drug-resistant tuberculosis among patients attending a tuberculosis unit of West Bengal', it has been observed that the prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) is highest in India and ranks first in the global ranking of detecting new cases each year. In addition, as per the same source, an estimated overall incidence of tuberculosis in India was 193 per lakh people, in 2020. Similarly, as per the latest report of the Government of India published in March 2021, there were an estimated 1,24,000 instances of MDR/RR-TB in India (9.1 lakh people), in 2021. Thus, the rising burden of MDR-TB cases among the population is expected to increase the demand for early diagnosis of the disease for further treatment, which in turn is anticipated to augment the market growth over the forecast period.

Furthermore, the growing company's focus on research and development activities and intensive product pipelines are also contributing to the growth of the market. For instance, in October 2021, Qiagen launched the QIAreach QuantiFERON-TB test, built on the proven QuantiFERON-TB Gold Plus technology for tuberculosis (TB) infection. Also, in July 2020, The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, launched a new drug-resistant tuberculosis profiling test, Xpert MTB/XDR, that can be used to empower clinicians to quickly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB). The test can give a result in 90 minutes.

However, the high costs associated with tuberculosis diagnostics and low coverage or absence of insurance in the emerging markets are some of the factors that are hindering the market growth over the forecast period.

Tuberculosis Diagnostics Industry Segmentation

As per the scope of the report, Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it remains one of the most common causes of death among adults, particularly in emerging economies. The government initiatives for promoting diagnoses of TB are increasing globally, as governments of various regions are beginning to understand the gap areas in TB management. The Tuberculosis Diagnostics Market is segmented by Diagnostic Test Type (Radiographic Test, Laboratory Test, Nucleic Acid Testing, Cytokine Detection Test, Drug Resistance Test, and Other Diagnostic Test Types), End-User (Hospital/Clinics, Diagnostics/Research Laboratory, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Diagnostic Test Type
Radiographic Test
Laboratory Test
Nucleic Acid Testing
Cytokine Detection Test
Drug Resistance Test
Other Diagnostic Test Types
By End User
Hospital/Clinics
Diagnostics/Research Laboratory
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Tuberculosis Diagnostics Market Size Summary

The tuberculosis diagnostics market is poised for significant growth over the forecast period, driven by the increasing incidence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) globally. The market is experiencing a resurgence in demand for advanced diagnostic tests and treatments, particularly in regions with high TB burdens such as South-East Asia, Africa, and the Western Pacific. The COVID-19 pandemic had a detrimental impact on TB diagnosis and treatment, leading to a decrease in TB detection and an increase in mortality due to resource reallocation and healthcare system strain. However, the market is expected to recover and expand, supported by rising research and development investments, government initiatives, and heightened awareness in emerging markets.

The adoption of nucleic acid testing is a key factor propelling market growth, offering advantages such as improved accuracy and faster results compared to traditional microscopy tests. The introduction of advanced molecular diagnostic technologies and tests, such as the QIAreach QuantiFERON-TB test and the Xpert MTB/XDR test, is expected to enhance diagnostic capabilities and drive market expansion. North America is anticipated to dominate the market due to its well-established healthcare infrastructure and high healthcare spending, despite the rising number of TB cases. The competitive landscape is characterized by strategic initiatives such as new product launches, collaborations, and regional expansions by key players like Abbott, Becton, Dickinson and Company, and Cepheid, among others.

Explore More

Global Tuberculosis Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Burden of Tuberculosis and Multidrug-resistant Tuberculosis (MDR-TB)

      2. 1.2.2 Increasing R&D Investments and Intensive Product Pipelines

      3. 1.2.3 Increasing Government Initiatives and Rising Awareness in the Emerging Markets

    3. 1.3 Market Restraints

      1. 1.3.1 High Costs Associated with Tuberculosis Diagnostics

      2. 1.3.2 Low Coverage or Absence of Insurance in the Emerging Markets

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 2.1 By Diagnostic Test Type

      1. 2.1.1 Radiographic Test

      2. 2.1.2 Laboratory Test

      3. 2.1.3 Nucleic Acid Testing

      4. 2.1.4 Cytokine Detection Test

      5. 2.1.5 Drug Resistance Test

      6. 2.1.6 Other Diagnostic Test Types

    2. 2.2 By End User

      1. 2.2.1 Hospital/Clinics

      2. 2.2.2 Diagnostics/Research Laboratory

      3. 2.2.3 Other End Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East & Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Tuberculosis Diagnostics Market Size FAQs

The Global Tuberculosis Diagnostics Market size is expected to reach USD 2.44 billion in 2024 and grow at a CAGR of 5.87% to reach USD 3.24 billion by 2029.

In 2024, the Global Tuberculosis Diagnostics Market size is expected to reach USD 2.44 billion.

Tuberculosis Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)